Palbociclib

• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 Phase III 6 countries Eli Lilly & Co.
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting
  2024-512360-55-00 Phase II 9 countries Medica Scientia Innovation Research S.L.
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting
  2024-516162-11-00 Phase III 5 countries F. Hoffmann-La Roche AG
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting
  2023-507305-33-00 Phase I (FiH) 1 country Astrazeneca AB
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting
  2022-502980-39-00 Phase III 13 countries F. Hoffmann-La Roche AG
• IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-contr… Recruiting
  2023-506620-87-00 Phase III/IV 6 countries Region Oerebro Laen
• Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting
  2023-504141-31-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 Phase II 1 country The Royal Marsden NHS Foundation Trust
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting
  2024-513372-18-00 Phase II 1 country Consorzio Oncotech
• A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting
  2023-503629-20-00 Phase I/II 3 countries F. Hoffmann-La Roche AG
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended
  2024-512925-95-00 Phase III 16 countries Pfizer Inc.
• PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial Ended
  2024-519364-40-00 Phase II 1 country Helse Bergen HF
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended
  2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
• Phase 3, Randomized, Open-Label Study of ARV-471 (PF-07850327) Plus Palbociclib vs Letrozole Plus Palbociclib in Participants With ER(+)/HER… Ended
  2022-500545-24-00 Phase III 4 countries Pfizer Inc.
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended
  2022-502145-10-00 Phase III 12 countries Celcuity Inc.
• PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR A… Ended
  2024-515492-34-00 Phase I/II 1 country Pfizer Inc.
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended
  2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended
  2023-504997-39-00 Phase III 8 countries AstraZeneca AB
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III 13 countries AstraZeneca AB
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended
  2023-506911-16-00 Phase III 11 countries F. Hoffmann-La Roche AG

Showing 1–24 of 39 trials